These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25702706)

  • 21. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia.
    Blom DJ; Averna MR; Meagher EA; du Toit Theron H; Sirtori CR; Hegele RA; Shah PK; Gaudet D; Stefanutti C; Vigna GB; Larrey D; Bloedon LT; Foulds P; Rader DJ; Cuchel M
    Circulation; 2017 Jul; 136(3):332-335. PubMed ID: 28716835
    [No Abstract]   [Full Text] [Related]  

  • 22. MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia.
    Kolovou GD; Kolovou V; Papadopoulou A; Watts GF
    J Atheroscler Thromb; 2016 Jul; 23(7):878-83. PubMed ID: 27170061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
    Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
    Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.
    Averna M; Cefalù AB; Stefanutti C; Di Giacomo S; Sirtori CR; Vigna G
    Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):36-44. PubMed ID: 26723464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia.
    Rizzo M
    IDrugs; 2010 Feb; 13(2):103-11. PubMed ID: 20127562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them.
    Yoshida H
    J Atheroscler Thromb; 2017 Apr; 24(4):390-392. PubMed ID: 28239069
    [No Abstract]   [Full Text] [Related]  

  • 27. Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review.
    Neef D; Berthold HK; Gouni-Berthold I
    Expert Rev Clin Pharmacol; 2016; 9(5):655-63. PubMed ID: 26943823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.
    Cuchel M; Meagher EA; du Toit Theron H; Blom DJ; Marais AD; Hegele RA; Averna MR; Sirtori CR; Shah PK; Gaudet D; Stefanutti C; Vigna GB; Du Plessis AM; Propert KJ; Sasiela WJ; Bloedon LT; Rader DJ;
    Lancet; 2013 Jan; 381(9860):40-6. PubMed ID: 23122768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
    Roeters van Lennep J; Averna M; Alonso R
    J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis.
    Blom DJ; Raal FJ; Santos RD; Marais AD
    Curr Atheroscler Rep; 2019 Nov; 21(12):48. PubMed ID: 31741187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia.
    Harada-Shiba M; Koezuka R; Makino H; Ogura M
    J Atheroscler Thromb; 2023 Feb; 30(2):203-205. PubMed ID: 35732425
    [No Abstract]   [Full Text] [Related]  

  • 32. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
    Marbach JA; McKeon JL; Ross JL; Duffy D
    Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iomitapide (Lojuxta). Use only in homozygous familial hypercholesterolaemia, with caution.
    Prescrire Int; 2015 Jul; 24(162):176-8. PubMed ID: 26240881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy.
    D'Erasmo L; Cefalù AB; Noto D; Giammanco A; Averna M; Pintus P; Medde P; Vigna GB; Sirtori C; Calabresi L; Pavanello C; Bucci M; Sabbà C; Suppressa P; Natale F; Calabrò P; Sampietro T; Bigazzi F; Sbrana F; Bonomo K; Sileo F; Arca M
    Adv Ther; 2017 May; 34(5):1200-1210. PubMed ID: 28432645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microsomal transfer protein inhibition in humans.
    Cuchel M; Rader DJ
    Curr Opin Lipidol; 2013 Jun; 24(3):246-50. PubMed ID: 23594709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder.
    Smith RJ; Hiatt WR
    JAMA Intern Med; 2013 Sep; 173(16):1491-2. PubMed ID: 23649296
    [No Abstract]   [Full Text] [Related]  

  • 37. New pharmacologic treatments for familial hypercholesterolemia.
    McDonough A; Matura LA; Carroll D
    Nurs Womens Health; 2013 Oct; 17(5):443-7. PubMed ID: 24138664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
    Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
    J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice.
    Marbach JA; Thapa J; Goldenberg E; Duffy D
    Del Med J; 2015 Aug; 87(8):238-43. PubMed ID: 26402926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
    Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.